Krystal Biotech Inc (Krystal Biotech) is a gene therapy company that carries out the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs, especially dermatological diseases. The company’s only marketed product is VYJUVEK/B-VEC (bercolagene telserpavec), which is a gene therapy for the treatment of dystrophic epidermolysis bullosa (DEB). Krystal Biotech uses its patented gene therapy technology platform based on engineered HSV-1 to create vectors that deliver therapeutic transgenes to cells of interest in multiple organ systems. The company’s pipeline products include KB105, KB407, KB104, KB408, and KB707. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania, the US.
Krystal Biotech Inc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
VYJUVEK (B-VEC- Bercolagene Telserpavec): | VYJUVEK |
Dystrophic Epidermolysis Bullosa (DEB) | |
Pipeline | |
XYZ | |
XYZ | |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Regulatory Approval | In February, the company received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for inhaled KB707 for the treatment of patients with solid tumors with pulmonary metastases that are relapsed or refractory to standard of care therapy. |
2023 | Regulatory Approval | In December, the company received Orphan Drug Designation (ODD) from the Japan Ministry of Health, Labour and Welfare (MHLW) for beremagene geperpavec-svdt (B-VEC or VYJUVEK) for the treatment of dystrophic epidermolysis bullosa (DEB). |
2023 | Regulatory Approval | In September, the company received the Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for KB408 for the treatment of alpha-1 antitrypsin deficiency (AATD). |
Competitor Comparison
Key Parameters | Krystal Biotech Inc | Johnson & Johnson | Merck & Co Inc | Pfizer Inc | AbbVie Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
City | Pittsburgh | New Brunswick | Kenilworth | New York | North Chicago |
State/Province | Pennsylvania | New Jersey | New Jersey | New York | Illinois |
No. of Employees | 229 | 131,900 | 72,000 | 88,000 | 50,000 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Krish S. Krishnan | Chief Executive Officer; Chairman | Executive Board | 2016 | 59 |
Kathryn Romano | Executive Vice President; Chief Accounting Officer | Senior Management | 2020 | 43 |
Suma M. Krishnan | Director; President - Research and Development | Executive Board | 2022 | 59 |
Christine Wilson | Head - US Sales and Marketing | Senior Management | - | - |
Laurent Goux | Senior Vice President; General Manager - Europe | Senior Management | - | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer